Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.